Overview
Dr. Ohman, Professor of Medicine, received medical degrees from the Royal College of Surgeons in Ireland and the National University of Ireland (1984, Fellowship 1984-1987), and completed his training in cardiology at Duke University (1987-1991), where he has remained on faculty. In 2001, he became Chief of Cardiology at the University of North Carolina at Chapel Hill, where he founded the UNC Heart Center and became its first director. In 2005 he returned to Duke to pursue his interest in advanced coronary disease as the Director of the Program for Advanced Coronary Disease. Since that time, he has been appointed to Associate Director of the Duke Heart Center, the Kent and Siri Rawson Director for the Program for Advanced Coronary Disease, and most recently, Vice-Chair of Development and Innovation in the Department of Medicine.
Dr. Ohman’s clinical and research interests include interventional cardiology and high-risk supported PCI, and treatment of patients with advanced/complex coronary disease. He has researched how to improve patient care through the use of guidelines-based therapies and adherence, and examining global cardiovascular risk and health. He has been a participant on numerous guidelines writing committees, served on the ACC/AHA oversight committee for guidelines development, and has served on the steering committees for trials on ST-elevation myocardial infarction and non-ST-elevation ACS. He is a consultant to the National Institutes of Health, and a consultant for the FDA Advisory Panel for Cardiovascular Devices.
Dr. Ohman has published over 600 peer-reviewed papers and three books in cardiovascular medicine. He holds three U.S. patents in reperfusion therapy. He is an associate editor for the American Heart Journal and serves on the editorial boards of the Journal of the American College of Cardiology and the American Journal of Cardiology. He is a Fellow of the Royal College of Physicians in Ireland, the Royal Society of Medicine (U.K.), the European Society of Cardiology, the Society of Cardiac Angiography and Interventions, and the American College of Cardiology.
Current Appointments & Affiliations
Recent Publications
Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial.
Journal Article J Am Coll Cardiol · February 11, 2025 Full text Link to item CiteImpact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial.
Journal Article Eur Heart J Cardiovasc Pharmacother · February 8, 2025 AIMS: In standard time-to-first event analysis, early aspirin discontinuation followed by ticagrelor monotherapy has been shown to reduce bleeding without increasing ischaemic complications compared with ticagrelor plus aspirin after percutaneous coronary ... Full text Link to item CiteThe Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry.
Journal Article J Card Fail · October 2024 INTRODUCTION: Little is known about the use of cangrelor in patients with myocardial infarction (MI) presenting with cardiogenic shock (CS). METHODS: CAMEO (Cangrelor in Acute MI: Effectiveness and Outcomes) is a multicenter observational registry evaluati ... Full text Link to item CiteRecent Grants
cVAD and QI Registries Manuscripts
ResearchPrincipal Investigator · Awarded by Abiomed · 2019 - 2022CRISP-AMI Data Analysis
ResearchPrincipal Investigator · Awarded by Abiomed · 2018 - 2019DCRI CERT for Cardiovascular Therapies
ResearchCo Investigator · Awarded by National Institutes of Health · 1999 - 2002View All Grants